CII
TEVA icon

CR Intrinsic Investors’s Teva Pharmaceuticals TEVA Stock Holding History

CR Intrinsic Investors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-800,000
Closed -$42.3M – 153
2014
Q1 		$42.3M Buy
+800,000
New +$37M 1.58% 4

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

CR Intrinsic Investors's TEVA Position: Q2 2014 in Review

CR Intrinsic Investors sold out of Teva Pharmaceuticals (TEVA) in Q2 2014, closing a stake of 800,000 shares — an estimated $42.3M sold.

CR Intrinsic Investors first reported a position in TEVA in Q1 2014 and held it in 1 quarter. The position peaked at $42.3M in Q1 2014. 780 funds tracked by Wall St. Rank hold TEVA as of Q2 2014.

  • CR Intrinsic Investors reported no remaining Teva Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • CR Intrinsic Investors sold 800,000 Teva Pharmaceuticals shares in Q2 2014, an estimated $42.3M.
  • CR Intrinsic Investors first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • CR Intrinsic Investors's Teva Pharmaceuticals position peaked at $42.3M in Q1 2014.
  • 780 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2014.

Based on CR Intrinsic Investors's 13F filing for Q2 2014.